14005-52-8

Basic information

• Product Name: Quinazoline, 2-(4-methyl-1-piperazinyl)-4-phenyl-
• CAS NO: 14005-52-8
• Molecular Formula: C19H20N4
• Molecular Weight: 304.395
• Mol File: 14005-52-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Quinazoline, 2-(4-methyl-1-piperazinyl)-4-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinazoline, 2-(4-methyl-1-piperazinyl)-4-phenyl-(14005-52-8)
• EPA Substance Registry System: Quinazoline, 2-(4-methyl-1-piperazinyl)-4-phenyl-(14005-52-8)

Safety Data

• Hazardous Substances Data: 14005-52-8(Hazardous Substances Data)

Upstream product

• 13047-06-8 o-bromobenzophenone 
• 28457-20-7 N-methylpiperazine carboxamidine sulfate 
• 109-01-3 1-methyl-piperazine 
• 29874-83-7 2-chloro-4-phenylquinazoline 

Relevant articles and documents

Structure-activity relationship studies of CNS agents. Part 29. N-Methylpiperazino-substituted derivatives of quinazoline, phthalazine and quinoline as novel α1, 5-HT(1A) and 5-HT(2A) receptor ligands

New N-methylpiperazino-substituted quinazolines 8 and 9, phthalazine 13, and quinoline 19 have been synthesized. The receptor binding profiles (α1, 5-HT(1A), 5-HT(2A)) of these compounds and their analogs (7-22) have been determined. It has been demonstrated that orientation of a local dipole moment of the heteroaromatic ring system affects both the α1 and 5-HT(2A) affinity of the investigated class of ligands. Distortion of the coplanar unfused heteroaromatic ring system results in a decreased 5-HT(2A) affinity. 4-(4-Methylpiperazino)-2-(2-thienyl)quinoline 18 is the most active and selective α1 ligand (K(i) = 4.9 nM) with a much lower affinity for 5-HT(1A) (K(i) = 3420 nM) and 5-HT(2A) (K(i) = 211 nM) receptors.

Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders

This invention relates to compounds of the formula 1 wherein R1, R2, and R3 and R4 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.